Detail akcie CANTON STRATEGIC HOLDINGS INC online

Business Summary: Canton Strategic Holdings, Inc., formerly Tharimmune, Inc., is advancing institutional blockchain adoption to drive the digitization of financial markets. In addition to driving value through activities on the Canton Network, the Company operates a Super Validator, ensuring safe and secure transactions across the Network. The Company also operates a clinical-stage biotech research and development arm. Its lead clinical asset, GV104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter high-potency opioids. The expanded pipeline includes other indications for GV104 and GV023, a new approach to autoimmune diseases, as well as an early-stage multispecific biologic platform.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Canton Strategic Holdings Inc revenues was not reported. Net loss decreased 22% to $6.5M. Lower net loss reflects Pre-clinical biotechnology segment loss decrease of 24% to $6.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$7.75 to -$1.97.